Pfizer Dividenden en inkoop

Dividend criteriumcontroles 4/6

Pfizer is een dividendbetalend bedrijf met een huidig rendement van 6.76%. Volgende betalingsdatum is op 1st December, 2025 met een ex-dividenddatum van 7th November, 2025.

Belangrijke informatie

6.8%

Dividendrendement

n/a

Terugkoop Rendement

Totaal aandeelhoudersrendement	n/a
Toekomstig dividendrendement	7.0%
Dividendgroei	4.2%
Volgende betaaldatum dividend	01 Dec 25
Ex-dividenddatum	07 Nov 25
Dividend per aandeel	n/a
Uitbetalingsratio	99%

Recente updates van dividend en inkoop

Recent updates

It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope

Apr 17

Pfizer: Tasty 7% Yield

Apr 16

R&D And Savings Programs Will Strengthen Future Outlook

Apr 08 Focus on R&D productivity in 2025 may risk misalignment with market needs, impacting future revenue if new products underperform.

Oncology Integration And Phase III Trials Will Redefine Future

Apr 07 Pfizer's oncology focus strengthens its portfolio and future revenue through Seagen integration and promising R&D pipeline developments in oncology and vaccines.

Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)

Mar 28

Pfizer: Bulls Need To Check Out Its Graham P/E

Mar 22

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

Mar 20I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines

Pfizer: Undervalued Safe Haven In Risk-Off Market

Mar 11

Pfizer Remains A Good Pick For Dividend Investors

Mar 04

Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)

Feb 28

Why Pfizer's Stock Price Isn't Reflecting Its True Value

Feb 19

Pfizer: 3 Key Risks That Warrant A Sell

Feb 12

Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down

Feb 04

These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively

Feb 04

Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider

Jan 28

Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's

Jan 13

Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy

Jan 13

Pfizer: One Of The Next Big AI Winners

Dec 30

Pfizer (NYSE:PFE) Is Paying Out A Larger Dividend Than Last Year

Dec 30

Pfizer: Time And Patience Ran Out (Rating Downgrade)

Dec 24

Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call

Dec 18

Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43

Dec 16

Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns

Dec 11

Pfizer: Too Cheap To Ignore

Dec 05

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Het dividend per aandeel van PFE is de afgelopen 10 jaar stabiel gebleven.

Groeiend dividend: De dividendbetalingen van PFE zijn de afgelopen 10 jaar gestegen.

Dividendrendement versus markt

Pfizer Dividendrendement versus markt

Hoe verhoudt PFE dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (PFE)	6.8%
Markt onderkant 25% (US)	1.5%
Markt Top 25% (US)	4.6%
Gemiddelde industrie (Pharmaceuticals)	2.2%
Analist prognose (PFE) (tot 3 jaar)	7.0%

Opmerkelijk dividend: Het dividend van PFE ( 6.76% ) is hoger dan dat van de onderste 25% van de dividendbetalers op de US markt ( 1.53% ).

Hoog dividend: Het dividend van PFE ( 6.76% ) behoort tot de top 25% van dividendbetalers in de US markt ( 4.56% )

Winstuitkering aan aandeelhouders

Verdiendekking: Gezien de hoge payout ratio ( 98.5% ) worden de dividendbetalingen van PFE niet goed gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Gezien de hoge cash payout ratio ( 94.3% ) worden de dividendbetalingen van PFE niet goed gedekt door de kasstromen.

Ontdek bedrijven met een sterk dividend

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/11/18 09:17
Aandelenkoers aan het einde van de dag	2025/11/18 00:00
Inkomsten	2025/09/28
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Pfizer Inc. wordt gevolgd door 47 analisten. 24 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
David Toung	Argus Research Company
Kerry Holford	Berenberg
Luisa Hector	Berenberg

Pfizer Dividenden en inkoop

Dividend criteriumcontroles 4/6

Belangrijke informatie

Recente updates van dividend en inkoop

Upcoming dividend of US$0.43 per share

Second quarter dividend of US$0.43 announced

Upcoming dividend of US$0.43 per share

First quarter dividend of US$0.43 announced

Fourth quarter dividend of US$0.43 announced

Pfizer Inc. Declares Second-Quarter 2025 Dividend, Payable on June 13, 2025

Recent updates

Pfizer Inc. (NYSE:PFE) completed the acquisition of Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others.

Pfizer Reportedly Looks to Sell Stake in Pandemic Vaccine Partner BioNTech

Pfizer Gets Metsera: Why The $20.65 CVR Is Highly Likely To Pay Out (In Part)

Third quarter 2025 earnings: EPS exceeds analyst expectations

Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025

Upcoming dividend of US$0.43 per share

Pfizer Inc. Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

Pfizer Inc. and Astellas Pharma U.S. Inc. Announces Final Overall Survival Results from the Phase 3 EMBARK Study Evaluating XTANDI

Pfizer Inc. Announces Positive Topline Results from the Phase 3 Her2climb-05 Trial of First-Line Combination Therapy with the Tyrosine Kinase Inhibitor Tukysa®?

Second quarter dividend of US$0.43 announced

Investor sentiment improves as stock rises 15%

Hearing Against Pfizer Set for 29 September in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin Papantonio

Pfizer Inc. to Report Q3, 2025 Results on Nov 04, 2025

New major risk - Revenue and earnings growth

Pfizer Inc. (NYSE:PFE) agreed to acquire Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others for $5 billion.

Arbutus Pharma Corp. and Genevant Sciences GmbH Provides Lawsuit Update

Nastlaw LLC and Direct Purchaser Plaintiffs Announce Additional Settlements in Re Generic Pharmaceutical Pricing Antitrust Litigation

Pfizer Inc. and BioNTech SE Announce Topline Data Demonstrating Robust Immune Response with Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Olema Pharmaceuticals, Inc. Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

Enanta Pharmaceuticals, Inc. Files Patent Infringement Suit Against Pfizer Inc. in the Unified Patent Court of the European Union

Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025

BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA Vaccine

Pfizer's 'Depo-Provera' Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill

Upcoming dividend of US$0.43 per share

Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDI

First quarter dividend of US$0.43 announced

Pfizer Inc. Announces Positive Topline Phase 3 Results for Hympavzi™? in Hemophilia A or B with Inhibitors

Arvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Pfizer Inc. Announces Statically Significant and Clinically Significant Results from the Phase 3 BREAKWATER Trial Evaluating BRAFTOVI®? (Encorafenib) in Combination with Cetuximab and mFOLFOX6

Case Management Conference in the Depo-Provera Legal Action Against Pfizer Inc

Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2

Pfizer's Q1 Update May Mark A Bottom In The Stock

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Pfizer Inc. Reaffirms Earnings Guidance for the Year 2025

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naive, High-Risk Non-Muscle Invasive Bladder Cancer

Fourth quarter dividend of US$0.43 announced

Pfizer Inc. Declares Second-Quarter 2025 Dividend, Payable on June 13, 2025

Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle

It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope

ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO to Include Adults Aged 50 to 59 At Increased Risk of Disease

Pfizer: Tasty 7% Yield

Pfizer Inc. Provides Update on Oral Glp-1 Receptor Agonist Danuglipron

R&D And Savings Programs Will Strengthen Future Outlook

Oncology Integration And Phase III Trials Will Redefine Future

Entwistle & Cappucci LLP Files Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc

European Commission Approves Pfizer's RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)

Pfizer: Bulls Need To Check Out Its Graham P/E

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

Pfizer Inc. to Report Q1, 2025 Results on Apr 29, 2025

Pfizer Inc., Annual General Meeting, Apr 24, 2025

Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical Trial

Pfizer: Undervalued Safe Haven In Risk-Off Market​

Pfizer Remains A Good Pick For Dividend Investors

Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)

Chairman of the Board & CEO exercised options and sold US$904k worth of stock

Insider exercised options and sold US$243k worth of stock

Why Pfizer's Stock Price Isn't Reflecting Its True Value

Pfizer’s TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

U.S. FDA Approves Pfizer's ADCETRIS Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Pfizer: 3 Key Risks That Warrant A Sell

Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer

Pfizer Inc. Provides Earnings Guidance for the Year 2025

Full year 2024 earnings: EPS misses analyst expectations

Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down

These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively

Pfizer: Undervalued Safe Haven In Risk-Off Market